An NMR-Based Model to Investigate the Metabolic Phenoreversion of COVID-19 Patients throughout a Longitudinal Study.
Clicks: 182
ID: 276234
2022
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
182 views
47 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #16 of 17 articles by views in Metabolites
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
After SARS-CoV-2 infection, the molecular phenoreversion of the immunological response and its associated metabolic dysregulation are required for a full recovery of the patient. This process is patient-dependent due to the manifold possibilities induced by virus severity, its phylogenic evolution and the vaccination status of the population. We have here investigated the natural history of COVID-19 disease at the molecular level, characterizing the metabolic and immunological phenoreversion over time in large cohorts of hospitalized severe patients (n = 886) and non-hospitalized recovered patients that self-reported having passed the disease (n = 513). Non-hospitalized recovered patients do not show any metabolic fingerprint associated with the disease or immune alterations. Acute patients are characterized by the metabolic and lipidomic dysregulation that accompanies the exacerbated immunological response, resulting in a slow recovery time with a maximum probability of around 62 days. As a manifestation of the heterogeneity in the metabolic phenoreversion, age and severity become factors that modulate their normalization time which, in turn, correlates with changes in the atherogenesis-associated chemokine MCP-1. Our results are consistent with a model where the slow metabolic normalization in acute patients results in enhanced atherosclerotic risk, in line with the recent observation of an elevated number of cardiovascular episodes found in post-COVID-19 cohorts.
| Reference Key |
gilredondo2022anmetabolites
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Gil-Redondo, Rubén;Conde, Ricardo;Bizkarguenaga, Maider;Bruzzone, Chiara;Laín, Ana;González-Valle, Beatriz;Iriberri, Milagros;Ramos-Acosta, Carlos;Anguita, Eduardo;Arriaga Lariz, Juan Ignacio;España Yandiola, Pedro Pablo;Moran, Miguel Ángel;Jiménez-Mercado, Mario Ernesto;Egia-Mendikute, Leire;Seco, María Luisa;Schäfer, Hartmut;Cannet, Claire;Spraul, Manfred;Palazón, Asís;Embade, Nieves;Lu, Shelly C;Wist, Julien;Nicholson, Jeremy K;Mato, José M;Millet, Oscar; |
| Journal | Metabolites |
| Year | 2022 |
| DOI |
1206
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.